Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer.
Tadaaki YamadaSoichi HiraiYuki KatayamaAkihiro YoshimuraShinsuke ShiotsuSatoshi WatanabeToshiaki KikuchiKazuki HiroseYutaka KubotaYusuke ChiharaTaishi HaradaKeiko TanimuraTakayuki TakedaNobuyo TamiyaYoshiko KanekoUchino JunjiKoichi TakayamaPublished in: Cancer medicine (2019)
Patients with uncommon EGFR mutations and without T790M mutations are associated with the best outcomes for treatment with immunotherapy among those with EGFR-mutated NSCLC, based on retrospective analysis. Further research is needed to validate the clinical biomarkers involved in ICI responders with EGFR mutations.